Designing Phase 2 Trials Based on Program-Level Considerations: A Case Study for Neuropathic Pain
Nitin Patel(Cytel (United States)), José Cirı́aco Pinheiro(Janssen (Belgium)), James A. Bolognese(Cytel (United States)), Arnold R. Gammaitoni(Merck & Co., Inc., Rahway, NJ, USA (United States)), David Hewitt(Glasgow Royal Infirmary), Christy Chuang‐Stein(Pfizer (United States))
Cited by 28
Related Papers
Advances in Neuropathic Pain
|Archives of Neurology|2003|1.2k
Sources of variance in 24-hour dietary recall data: implications for nutrition study design and interpretation
|American Journal of Clinical Nutrition|1979|997
MALIGNANT DISEASE IN CHILDHOOD AND DIAGNOSTIC IRRADIATION IN UTERO
|The Lancet|1956|569
Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)
|Clinical Infectious Diseases|2015|340